The new OHSU Preventive Medicine Residency Program, which OHSU is launching in partnership with CareOregon, is among the topics discussed during an audio interview with CareOregon CEO Eric Hunter, M.B.A.

The OHSU Knight Cardiovascular Institute is participating in an American Heart Association initiative to address recurrent pericarditis, or inflammation of the sac-like structure that protects the heart.

OPB’s Think Out Loud hosts retired OHSU neurologist Daniel Gibbs, M.D., and his wife, Lois Seed, as they talk about Dr. Gibbs’ own diagnosis of Alzheimer’s disease and preview a public screening of a new documentary at 1:30 p.m. Saturday, June 22, in the OHSU Auditorium. The screening will be followed by a Q&A with Joseph Quinn, M.D.

OHSU School of Nursing La Grande Campus graduates participated in Eastern Oregon University’s 2024 commencement ceremony, and graduates of joint OHSU-Oregon Tech programs in paramedic education and medical laboratory science participated in Oregon Institute of Technology’s 2024 commencement ceremony.

Globe Newswire release by Oryzon references results from a clinical trial for acute myeloid leukemia led by OHSU.

The Madison-St. Claire Record notes that Martin Schreiber, M.D., is an expert witness for the state of Illinois regarding assault weapons.

Kathleen Carlson, Ph.D., joins Portland Metro Chamber panel to discuss violence prevention in and around Portland.

In a story in The Scientist about new advancements in understanding the network of connections between neurons in the brain, Arpiar Saunders, Ph.D., says, “There is striking genetic evidence that mutations associated with autism and schizophrenia are enriched in genes that encode synaptic proteins. … But we don’t have any way yet to build big picture, aerial descriptions of the type of connectivity changes that might be occurring, so that is our goal.”

Silicon Republic interviews Mark Pennesi, M.D, Ph.D., about promising results in the first 14 patients to undergo CRISPR-based gene editing to treat a rare form of blindness. He says, “It’s certainly possible that the younger we treat, we might be able to get better results. But even some of the older patients showed improvement as well, meaning that it may not be too late for many patients. In fact, I think one of our best patients was 59. I think we’re going to utilize this technology going forward for other genes."

In a Health story about paralytic shellfish poisoning likely caused by blooms of a particular type of ocean phytoplankton, Courtney Temple, M.D., says, “We typically see events like this during times of harmful algal blooms. There may be varying degrees of this marine algae during different time periods throughout the year, but it’s really this period of robust overgrowth that leads to excessive accumulation within the shellfish that makes it dangerous for consumption.”